Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis

Figure 1. Flow chart of the study population. AT, antithrombin; FORECAST, Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis and Trauma; rhTM, recombinant human thrombomodulin.

Figure 2. The Kaplan–Meier curves during the first 90 days for the cumulative survival of patients with and without anticoagulant therapy. The blue line represents the anticoagulant group and the dotted red line represents the non-anticoagulant group. Anticoagulant therapy was defined as the administration of antithrombin, recombinant human thrombomodulin, or their combination in the present study.

Figure 3. Regression line of hospital mortality of each treatment group estimated by the Cox proportional hazard regression model. (a) Two-way interaction term between the treatment and JAAM DIC score. (b) Three-way interaction term among anticoagulant therapy, the JAAM DIC score, and age. The lines indicate estimated log-transformed relative hazards, and the shaded areas represent 95% confidence intervals. The solid blue line represents patients in the anticoagulant group, and the dotted red line represents those in the non-anticoagulant group. JAAM, Japanese Association for Acute Medicine; DIC, disseminated intravascular coagulation. Anticoagulant therapy was defined as the administration of antithrombin, recombinant human thrombomodulin, or their combination in the present study.

Figure 4. Regression lines of the SOFA score 72 h after admission in each treatment group. (a) Two-way interaction term between the treatment and JAAM DIC score. (b) Three-way interaction term among anticoagulant therapy, JAAM DIC score, and age. The lines indicate estimated log-transformed relative hazards, and the shaded areas represent 95% confidence intervals. The solid blue line represents patients in the anticoagulant group, and the dotted red line represents those in the non-anticoagulant group. Anticoagulant therapy was defined as the administration of antithrombin, recombinant human thrombomodulin, or their combination in the present study. JAAM, Japanese Association for Acute Medicine; DIC, disseminated intravascular coagulation; SOFA, Sequential Organ Failure Assessment.